Overall, genetic studies across multiple species strongly support a role for Agpat5 in metabolic diseases, including hyperinsulinemia, glucose intolerance, metabolic dysfunction-associated steatotic liver disease (MASLD), and dyslipidemia. This evidence concerns the gene AGPAT5 and metabolic dysfunction-associated steatotic liver disease.